论文部分内容阅读
丙型肝炎(HC)可见于世界各地,占输血后肝炎的大部分,常易变或慢性,部分可发展或肝硬化、肝癌。HC目前尚无满意的治疗方法。干扰素对HC虽有一定疗效,但费用昂贵、停药后复发率可高达50％,且有一定副作用,故临床上较难推广。有人曾用病毒唑治疗HC,但以HC病毒(HCV)RNA为评价标准者国内尚不多。我们曾以病毒唑治疗部分HC病人,并以HCVRNA变化评价其疗效。现将用药满3个月并有HCVRNA复查结果的部分病人的资料初步分析如下: 1 材料与方法 1.1 病人 均为1991年7月～1993年2月我院住院或门诊病人。全部为血清HCVRNA“+”,治疗2～3月后有HCVRNA复查资料者。
Hepatitis C (HC) can be found in all parts of the world, accounting for most of the post-transfusion hepatitis, often changeable or chronic, some can develop or cirrhosis, liver cancer. HC currently no satisfactory treatment. Although interferon on HC although a certain effect, but expensive, relapse rate after stopping up to 50%, and have some side effects, it is more difficult to promote clinical. Some people have been treated with ribavirin HC, but the HC virus (HCV) RNA as the evaluation criteria are not many domestic. We have ribavirin treatment of some patients with HC, and HCVRNA changes in the evaluation of its efficacy. Now the drug over 3 months and HCVRNA review of the results of some patients preliminary analysis of the data are as follows: 1 Materials and Methods 1.1 The patients were July 1991 to February 1993 hospital inpatient or outpatient. All for the serum HCVRNA “+”, after 2 to 3 months of HCVRNA review information.